Lipid metabolism enzyme ACSVL3 supports glioblastoma stem cell maintenance and tumorigenicity
© Sun et al.; licensee BioMed Central Ltd. 2014
Received: 2 October 2013
Accepted: 21 May 2014
Published: 4 June 2014
Targeting cell metabolism offers promising opportunities for the development of drugs to treat cancer. We previously found that the fatty acyl-CoA synthetase VL3 (ACSVL3) is elevated in malignant brain tumor tissues and involved in tumorigenesis. This study investigates the role of ACSVL3 in the maintenance of glioblastoma multiforme (GBM) stem cell self-renewal and the capacity of GBM stem cells to initiate tumor xenograft formation.
We examined ACSVL3 expression during differentiation of several GBM stem cell enriched neurosphere cultures. To study the function of ACSVL3, we performed loss-of-function by using small interfering RNAs to target ACSVL3 and examined stem cell marker expression, neurosphere formation and tumor initiation properties.
ACSVL3 expression levels were substantially increased in GBM stem cell enriched neurosphere cultures and decreased after differentiation of the neurospheres. Down-regulating ACSVL3 with small inhibiting RNAs decreased the expression of markers and regulators associated with stem cell self-renewal, including CD133, ALDH, Musashi-1 and Sox-2. ACSVL3 knockdown in neurosphere cells led to increased expression of differentiation markers GFAP and Tuj1. Furthermore, ACSVL3 knockdown reduced anchorage-independent neurosphere cell growth, neurosphere-forming capacity as well as self-renewal of these GBM stem cell enriched neurosphere cultures. In vivo studies revealed that ACSVL3 loss-of-function substantially inhibited the ability of neurosphere cells to propagate orthotopic tumor xenografts. A link between ACSVL3 and cancer stem cell phenotype was further established by the findings that ACSVL3 expression was regulated by receptor tyrosine kinase pathways that support GBM stem cell self-renewal and tumor initiation, including EGFR and HGF/c-Met pathways.
Our findings indicate that the lipid metabolism enzyme ACSVL3 is involved in GBM stem cell maintenance and the tumor-initiating capacity of GBM stem cell enriched-neurospheres in animals.
KeywordsLipid metabolism ACSVL3 Glioblastoma Cancer stem cell Differentiation Tumorigenicity
Targeting cancer specific metabolism represents an opportunity to develop novel, potentially selective and broadly applicable drugs to treat a multiplicity of cancer types. Malignant tissues require large amounts of lipid for membrane biosynthesis, energy, and signal transduction during tumor progression . De novo fatty acid synthesis is the main means of fatty acid supply in cancers, therefore, enzymes involved in fatty acid metabolism have been implicated in cancer biology . For example, overexpression of fatty acid synthase results in enhanced lipogenesis, a common feature in a variety of human cancers, including primary brain tumors [3, 4]; and inhibiting fatty acid synthase or lipogenesis induces cancer cell death . In addition to fatty acid synthase, several other enzymes involved in lipid metabolism have recently been shown to be involved in tumor growth and malignancy [6, 7]. These data show that enzymes involved in lipid metabolism are potential therapeutic targets against cancers.
Human cells contain 26 genes encoding ACSs [9, 10]. Phylogenetically, ACSs are divided into at least four subfamilies that correlate with the chain length of their fatty acid substrates, although there is considerable overlap. There are short-chain ACS (ACSS), medium-chain ACS (ACSM), long-chain ACS (ACSL) and very long-chain ACS (ACSVL). Both ACSL and ACSVL isozymes are capable of activating fatty acids containing 16–18 carbons, which are among the most abundant in nature, but only the ACSVL family enzymes have significant ability to utilize substrates containing 22 or more carbons. Each ACS has a unique role in lipid metabolism based on tissue expression patterns, subcellular locations, and substrate preferences. For example, ACSL4 is overexpressed in breast, prostate, colon, and liver cancer specimens [11–13]. Among the multiple ACS members, two isozymes ACSL5 and ACSVL3, have been found important in gliomagenesis and malignancy [14, 15].
Many solid malignancies, including glioblastoma multiforme (GBM), exhibit a cellular hierarchy containing subsets of tumor cells with stem-like features, which are currently believed to disproportionately contribute to tumor growth and recurrence [16, 17]. These “cancer stem cells” display the capacity for long-term self-renewal, efficient propagation of tumor xenografts in experimental animals, the capacity for multi-lineage differentiation, and resistance to cytotoxic DNA-damaging agents [18, 19]. Understanding the mechanisms that regulate cancer stem cell self-renewal and tumor-propagating potential could lead to new and more effective anti-cancer strategies.
The influence of lipid metabolism pathways on cancer stem cells has not been explored in great detail. ACSVL3 (alternatively designated as FATP3, SLC27A3) is one of the most recently characterized members of the ACS family . Mouse ACSVL3 mRNA is found primarily in adrenal, testis, ovary, and developing brain; and ACSVL3 protein mainly localizes to subcellular vesicles that fractionate with mitochondria . Compared with normal brain tissues, ACSVL3 expression levels are elevated in clinical GBM specimens and induced in GBM cells following the activation of oncogenic receptor tyrosine kinases. We previously reported that ACSVL3 supports tumor promoting capacity in human GBM , a biological property attributed to the cancer stem cell phenotype. This current study examines the expression and function of ACSVL3 in GBM stem cell enriched neurosphere isolates. We show that ACSVL3 functions to support GBM stem cell self-renewal and the capacity of GBM stem cells to propagate tumor xenografts. Our results suggest that targeting ACSVL3-dependent lipid metabolic pathways could be a strategy for inhibiting GBM stem cells and their capacity to support tumor growth and recurrence.
All reagents were purchased from Sigma Chemical Co. (St. Louis, MO) unless otherwise stated. Hepatocyte growth factor (HGF) was a gift from Genentech (San Francisco, CA, USA). Epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) were purchased from Peprotech (Rocky Hill, NJ, USA). This study utilized discarded human pathological specimens from Johns Hopkins Neurological Operating Suite. Our use of de-identified pathological specimens as described here was reviewed by the John Hopkins IRB and designated to be “not human subjects research”.
GBM neurosphere culture and differentiation
Human glioblastoma neurosphere lines HSR-GBM1A (20913) and HSR-GBM1B (10627) were originally derived by Vescovi and colleagues . The GBM-DM14602 neurosphere line was derived from a glioblastoma at the University of Freiburg and kindly provided by Dr. Jaroslaw Maciaczy [21, 22]. The primary neurospheres JHH612, JHH626 and JHH710 were derived from discarded glioblastoma surgical specimens at Johns Hopkins Hospital using the same methods and culture conditions as described in Galli et al. [16, 23]. The primary neurosphere isolates were used at passage ≤ 10. All human materials were obtained and used in compliance with the Johns Hopkins IRB. GBM neurosphere cells were maintained in serum-free medium containing DMEM/F-12 (Life technologies, Carlsbad, CA), 1% BSA, EGF and FGF [16, 24, 25]. Cells were incubated in a humidified incubator containing 5% CO2 and 95% air at 37°C, and passaged every 4–5 days. Forced differentiation was performed according to the method of Galli et al.  with some modifications . Briefly, the neurosphere cells were cultured on Matrigel (BD Biosciences, Bedford, MA, USA)-coated surfaces in medium containing bFGF (no EGF) for 2 days and then grown in medium containing 1% fetal bovine serum (FBS) without EGF/FGF for 3–5 days.
Transient ACSVL3 knockdown was achieved using previously described ACSVL3 siRNA3 and ACSVL3 siRNA4 . Targeted sequences of siRNA 3 and siRNA4 corresponded to the human ACSVL3 coding region (total 2430 bp) at bp1243-1263 and 1855–1875, respectively. Transfections of ACSVL3 siRNAs were performed with Oligofectamine (Life technologies) according to the manufacturer’s instructions. Fifteen nmol/L of siRNA was incubated with GBM neurosphere cells for 72 hours.
Neurosphere-formation and clonogenic assays
Neurosphere cells were plated in six well plates. Cells were cultured in serum-free neurosphere medium for 5 days before being dissociated to single cell suspension and counted. For neurosphere formation assay, cells were grown for 5 days in medium containing EGF and FGF. Agarose (4%, Invitrogen) was then added to cultures to a final concentration of 1%. Immobilized neurospheres were stained with 1% Wright solution. For soft agar clonogenic assays, 1% agarose in DMEM was cast on the bottom of plastic six-well plates. Dissociated neurosphere cells (5 × 103cells/well in 6 well plates) were suspended in neurosphere culture medium containing 0.5% agarose and placed on top of the bottom layer. Cells were incubated in neurosphere culture medium for 7–14 days and colonies were fixed and stained with 1% Wright solution. The number of spheres or colonies (>100 μm in diameter) was measured in three random microscopic fields per well by computer-assisted morphometry (MCID, Linton, Cambridge, England). For serial dilution of sphere-formation assay, cells were incubated with control or ACSVL3 siRNA3 for 48 h and plated at the density of 25, 50 and 100 cells/well in of 48 well/plates. Wells containing neurospheres diameter were counted after 3 days.
Quantitative real time-PCR (qRT-PCR)
Total cellular RNA from GBM neurosphere cells was extracted using the RNeasy Mini kit (Qiagen, Germantown, MD, USA). The primer pairs used for amplifying genes of interest were: (1) ACSVL3: Forward primer 5′-cccagagtttctgtggctct-3′ and reverse primer 5′-ggacacttcagccagcaaat-3′ amplify a 256-bp intron-spanning ACSVL3 fragment; (2) nestin: forward primer 5′-aggatgtggaggtagtgaga-3′ and reverse primer 5′- ggagatctcagtggctctt-3′; (3) Musashi-1: forward primer 5′- gagactgacgcgccccagcc-3′ and reverse primer 5′-cgcctggtccatgaaagtgacg-3′; and (4) Sox-2: forward primer 5′- accggcggcaaccagaagaacag -3′ and reverse primer 5′- gcgccgcggccggtatttat -3′. Reverse transcription utilized MuLV Reverse Transcriptase and Oligo (dT) primers. Quantitative real-time PCR (qRT-PCR) was performed as we described in Ying et al. . Relative expression of each gene was normalized to 18S RNA.
The percentages of neurosphere cells expressing CD133 and ALDH were determined by analytical flow cytometry [21, 26]. For the cell surface marker CD133, single-cell suspensions in 100 μl assay buffer (phosphate buffered saline pH 7.2, 0.5% bovine serum albumin, 2 mM EDTA) were incubated with 10 μl of phycoerythrin (PE)-conjugated anti-CD133 antibody (clone 293C3, Miltenyi Biotec, Auburn, CA) for 10 min in the dark at 4°C. Alternatively, single-cell suspensions were incubated ± diethylaminobenzaldehyde (DEAB) and then incubated in ALDH substrate (Stem Cell Technologies, Vancouver, Canada). The stained cells were analyzed on a FACScan (BD Biosciences). For sorting CD133+ from CD133− cells, neurosphere cells were incubated with microbead-conjugated CD133 antibodies and isolated with magnetic columns (Miltenyi Biotec).
Immunoblotting and immunofluorescence staining
Immunoblotting analyses were performed as previously described . The primary antibodies used were: anti-ACSVL3 (1:1000) ; anti-β-actin (1:6000); anti-GFAP (1:500, DAKO, Carpinteria, CA, USA) and anti-Tuj1 (1:1000, EMD).
For immunofluorescence staining, neurosphere cells were collected by cytospin onto glass slides, fixed with 4% paraformaldehyde for 30 min at 4°C, permeabilized with PBS containing 0.5% Triton X-100 for 5 min and stained with anti-GFAP and anti-Tuj1 antibodies according to the manufacturers’ protocols. Secondary antibodies were conjugated with Alexa 488 or Cy3 (Life Technologies). Coverslips were placed with Vectashield antifade solution containing 4′6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA, USA). Immunofluorescent images were analyzed using Axiovision software (Carl Zeiss, Microscope, Thornwood, NY, USA).
Intracranial xenograft mouse models
All animal protocols were approved by the Johns Hopkins Animal Care and Use Committee. Orthotopic tumor xenograft formation was assessed in 4- to 6-wk-old female mice as previously described . HSR-GBM1A or HSR-GBM1B cells were transient transfected with ACSVL3 siRNAs for 3 days. Cell viability was determined by trypan blue dye exclusion. Equal numbers of viable cells (1×104 cells/animal) in 5 μL PBS were injected unilaterally into the caudate/putamen of C.B-17 SCID/beige mice (n = 10) under stereotactic control . The animals were sacrificed on post implantation week 10. Brains were removed, sectioned, and stained with H & E. Maximal tumor cross-sectional areas were measured by computer-assisted image analysis as previously described . Tumor volumes were estimated according to the following formula: tumor volume = (square root of maximum cross-sectional area)3.
Data were analyzed using Prism software (GraphPad, San Diego, CA, USA). When appropriate, two group comparisons were analyzed with a t test unless otherwise indicated. Multiple group comparisons were analyzed by one-way ANOVA with Bonferroni’s multiple comparison. All data are represented as mean value ± standard error of mean (SEM); n = 3 unless indicated otherwise. Significance was set at P < 0.05.
ACSVL3 expression correlates inversely with differentiation of GBM stem cells
ACSVL3 knockdown depletes GBM stem cell marker expression and promotes differentiation
ACSVL3 knockdown inhibits GBM neurosphere growth and abrogates tumor propagating capacity of GBM stem cell enriched neurospheres
A defining phenotype of cancer stem cells is their ability to propagate and maintain malignant tumors in vivo. We examined the effect of ACSVL3 knockdown on the orthotopic tumor propagating capacity of GBM neurosphere cells. HSR-GBM1A and GBM1B cells were treated with ACSVL3 siRNAs for 4 days in culture. Equal numbers of viable control and ACSVL3 siRNA-treated cells were implanted orthotopically into mice. ACSVL3 knockdown significantly reduced tumor initiation. All animals (n = 10) receiving control treated cells developed detectable intracranial tumors after 10 weeks. In contrast, only 40-50% of animals receiving ACSVL3 siRNA3-treated cells developed tumors (Figure 4E). This reduction in tumor initiation rate is consistent with the depletion of tumor-propagating cells in response to ACSVL3 knockdown.
Induction of ACSVL3 expression by receptor tyrosine kinase (RTK) activation
A thorough understanding of cancer cell metabolism is critical to the identification of new targets for therapeutic intervention. Lipid metabolism in cancer is one area that has in general been under-studied. The identification of OA-519, a marker of poor prognosis in breast cancer, as fatty acid synthase two decades ago  sparked new interest in this area of cancer metabolism. Several new synthetic fatty acid synthase inhibitors have shown promise in preclinical studies [32, 33]. However, to the best of our knowledge there are no current ongoing clinical trials testing drugs that target tumor lipid metabolism.
A significant issue in cancer therapeutics is that of recurrence and subsequent refractoriness to therapy. Tumor cells with stem-like features have been hypothesized to be, at least in part, responsible for these phenomena [16, 17]. Thus, drugs that target stem-like cells would be an invaluable weapon in the treatment arsenal. Our previous work suggested that the acyl-CoA synthetase ACSVL3 was overproduced in human GBM and GBM cells in culture, and that decreasing the expression of this enzyme in GBM cells reduced both their malignant behavior in culture and their tumorigenicity in nude mice . In this report, we show that expression of ACSVL3 is even more robust in cancer stem cell enriched neurospheres than in the cell population from which they were derived. Reducing ACSVL3 expression in these cells also decreased tumorigenicity in mice. Furthermore, differentiation of cancer stem cells with all-trans retinoic acid or Trichostatin A reduced ACSVL3 expression. Taken together, these observations indicate that ACSVL3 expression is associated with a highly undifferentiated phenotype and that therapeutic targeting this enzyme may be a promising anti-cancer therapy.
ACSVL3 is one of 26 acyl-CoA synthetases encoded by the human genome . Acyl-CoA synthetases activate fatty acids to their coenzyme A thioesters, allowing subsequent entry into diverse metabolic pathways. RNA interference studies suggest that ACSVL3 is responsible for up to 30% of long-chain and very-long chain acyl-CoA synthetase activity in cells that endogenously express the enzyme . Although this enzyme is also known as “fatty acid transport protein 3”, a role in fatty acid uptake could not be demonstrated experimentally . Results presented here, and our previous work , show a correlation between ACLVL3 levels and cell growth rate, suggesting that this enzyme may provide fatty acid substrates required for bulk membrane phospholipid biosynthesis. Our current studies do not support this hypothesis (Shi and Watkins, unpublished); rather, a role in lipid signaling, possibly via phosphoinositide species and PI3 kinase signaling , seems more likely. The induction of ACSVL3 by RTK oncogenic pathways supports this notion, and indicates the importance of fatty acid metabolism in cancer stem cell maintenance. Activated fatty acid can regulate oncogenic signaling transduction pathways that are necessary for cell survival, proliferation, and differentiation , either directly or indirectly, by functioning as agonists of a number of G protein-coupled receptors, activating RTK downstream targets such as phosphatidylinositol 3-kinase/Akt and p44/42 mitogen-activated protein kinases, and stimulating phospholipase C/protein kinase. Elucidation of the specific downstream lipid metabolism pathways that are “fed” by ACSVL3 will provide new clues as to how this enzyme supports the malignant phenotype, and this is currently an area of active investigation in our laboratory.
Lipid metabolism has been linked to cellular differentiation mechanisms in some in vitro and in vivo models. ACSVL4 (or fatty acid transporter protein 4) has been shown to regulate keratinocyte differentiation . Fatty acids and their metabolites can modulate stem cell self-renewal, survival, proliferation and differentiation by regulating gene expression, enzyme activity, and G protein-coupled receptor signal transduction . Recent studies revealed that arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) may regulate the proliferation and differentiation of various types of stem cells. For example, both AA and EPA were the most potent inhibitors of proliferation of promyelocytic leukemic cells [37, 38]. DHA or AA was found to promote the differentiation of neural stem cells into neurons by promoting cell cycle exit and suppressing cell death [39, 40]. The role of fatty acid metabolism pathways in cancer stem cell differentiation has not been explored. To our knowledge, this is the first report showing that ACSVL3 regulates cancer stem cell phenotype and that ACSVL3 loss-of-function promotes cancer stem cell differentiation and inhibits tumor-initiation properties of cancer stem cells.
Our findings suggest that ACSVL3 is a potential therapeutic target worthy of further investigation. Findings reported here suggest that if identified, a small molecule inhibitor of ACSVL3 could inhibit the growth of GBM stem cells as well as non-stem tumor cells. Although there have been a few inhibitors of acyl-CoA synthetases reported [41–44], most are non-specific, and none that target ACSVL3 have been described. Research efforts to discover specific ACSVL3 inhibiters are also underway.
Lipids regulate a broad spectrum of biological process that influences cell phenotype and oncogenesis. A better understanding of the biological function of lipid metabolism enzymes and cancer-specific lipid metabolic processes will enable us to identify new drug targets for cancer treatment. The results obtained in this study suggest that ACSVL3 is a potential therapeutic target in GBM. This is underlined by the fact that ACSVL3 is not essential for growth and survival of normal cells [20, 45]. Developing pharmacological inhibitors of ACSVL3 will propel forward our effort to target lipid mechanism in brain tumors.
This work is supported by NIH NS43987 (JL), NS073611 (JL), NS062043 (PW), and the James McDonnell Foundation (J. L.).
- Menendez JA, Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007, 7 (10): 763-777. 10.1038/nrc2222.View ArticlePubMedGoogle Scholar
- Kuhajda FP: Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition. 2000, 16 (3): 202-208. 10.1016/S0899-9007(99)00266-X.View ArticlePubMedGoogle Scholar
- Swinnen JV, Brusselmans K, Verhoeven G: Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care. 2006, 9 (4): 358-365. 10.1097/01.mco.0000232894.28674.30.View ArticlePubMedGoogle Scholar
- Tong L: Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery. Cell Mol Life Sci: CMLS. 2005, 62 (16): 1784-1803. 10.1007/s00018-005-5121-4.View ArticlePubMedGoogle Scholar
- Lupu R, Menendez JA: Pharmacological inhibitors of Fatty Acid Synthase (FASN)–catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?. Curr Pharm Biotechnol. 2006, 7 (6): 483-493. 10.2174/138920106779116928.View ArticlePubMedGoogle Scholar
- Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV: RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res. 2005, 65 (15): 6719-6725. 10.1158/0008-5472.CAN-05-0571.View ArticlePubMedGoogle Scholar
- Mashima T, Seimiya H, Tsuruo T: De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer. 2009, 100 (9): 1369-1372. 10.1038/sj.bjc.6605007.View ArticlePubMedPubMed CentralGoogle Scholar
- Watkins PA: Fatty acid activation. Prog Lipid Res. 1997, 36 (1): 55-83. 10.1016/S0163-7827(97)00004-0.View ArticlePubMedGoogle Scholar
- Watkins PA: Very-long-chain acyl-CoA synthetases. J Biol Chem. 2008, 283 (4): 1773-1777. 10.1074/jbc.R700037200.View ArticlePubMedGoogle Scholar
- Watkins PA, Ellis JM: Peroxisomal acyl-CoA synthetases. Biochim Biophys Acta. 2012, 1822 (9): 1411-1420. 10.1016/j.bbadis.2012.02.010.View ArticlePubMedPubMed CentralGoogle Scholar
- Cao Y, Dave KB, Doan TP, Prescott SM: Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma. Cancer Res. 2001, 61 (23): 8429-8434.PubMedGoogle Scholar
- Monaco ME, Creighton CJ, Lee P, Zou X, Topham MK, Stafforini DM: Expression of long-chain fatty acyl-CoA synthetase 4 in breast and prostate cancers is associated with sex steroid hormone receptor negativity. Transl Oncol. 2010, 3 (2): 91-98. 10.1593/tlo.09202.View ArticlePubMedPubMed CentralGoogle Scholar
- Sung YK, Park MK, Hong SH, Hwang SY, Kwack MH, Kim JC, Kim MK: Regulation of cell growth by fatty acid-CoA ligase 4 in human hepatocellular carcinoma cells. Exp Mol Med. 2007, 39 (4): 477-482. 10.1038/emm.2007.52.View ArticlePubMedGoogle Scholar
- Pei Z, Sun P, Huang P, Lal B, Laterra J, Watkins PA: Acyl-CoA synthetase VL3 knockdown inhibits human glioma cell proliferation and tumorigenicity. Cancer Res. 2009, 69 (24): 9175-9182. 10.1158/0008-5472.CAN-08-4689.View ArticlePubMedPubMed CentralGoogle Scholar
- Yamashita Y, Kumabe T, Cho YY, Watanabe M, Kawagishi J, Yoshimoto T, Fujino T, Kang MJ, Yamamoto TT: Fatty acid induced glioma cell growth is mediated by the acyl-CoA synthetase 5 gene located on chromosome 10q25.1-q25.2, a region frequently deleted in malignant gliomas. Oncogene. 2000, 19 (51): 5919-5925. 10.1038/sj.onc.1203981.View ArticlePubMedGoogle Scholar
- Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A: Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004, 64 (19): 7011-7021. 10.1158/0008-5472.CAN-04-1364.View ArticlePubMedGoogle Scholar
- Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature. 2004, 432 (7015): 396-401. 10.1038/nature03128.View ArticlePubMedGoogle Scholar
- Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006, 444 (7120): 756-760. 10.1038/nature05236.View ArticlePubMedGoogle Scholar
- Dirks PB: Brain tumor stem cells: the cancer stem cell hypothesis writ large. Mol Oncol. 2010, 4 (5): 420-430. 10.1016/j.molonc.2010.08.001.View ArticlePubMedGoogle Scholar
- Pei Z, Fraisl P, Berger J, Jia Z, Forss-Petter S, Watkins PA: Mouse very long-chain Acyl-CoA synthetase 3/fatty acid transport protein 3 catalyzes fatty acid activation but not fatty acid transport in MA-10 cells. J Biol Chem. 2004, 279 (52): 54454-54462. 10.1074/jbc.M410091200.View ArticlePubMedGoogle Scholar
- Ying M, Wang S, Sang Y, Sun P, Lal B, Goodwin CR, Guerrero-Cazares H, Quinones-Hinojosa A, Laterra J, Xia S: Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition. Oncogene. 2011, 30 (31): 3454-3467. 10.1038/onc.2011.58.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang SD, Rath P, Lal B, Richard JP, Li Y, Goodwin CR, Laterra J, Xia S: EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase. Oncogene. 2012, 31 (50): 5132-5243. 10.1038/onc.2012.16.View ArticlePubMedPubMed CentralGoogle Scholar
- Chaichana K, Zamora-Berridi G, Camara-Quintana J, Quinones-Hinojosa A: Neurosphere assays: growth factors and hormone differences in tumor and nontumor studies. Stem Cells. 2006, 24 (12): 2851-2857. 10.1634/stemcells.2006-0399.View ArticlePubMedGoogle Scholar
- Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, Piccirillo S, Vescovi AL, DiMeco F, Olivi A, Eberhart CG: Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells. 2007, 25 (10): 2524-2533. 10.1634/stemcells.2007-0166.View ArticlePubMedPubMed CentralGoogle Scholar
- Sun P, Xia S, Lal B, Eberhart CG, Quinones-Hinojosa A, Maciaczyk J, Matsui W, Dimeco F, Piccirillo SM, Vescovi AL, Laterra J: DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. Stem Cells. 2009, 27 (7): 1473-1486. 10.1002/stem.89.View ArticlePubMedPubMed CentralGoogle Scholar
- Li Y, Li A, Glas M, Lal B, Ying M, Sang Y, Xia S, Trageser D, Guerrero-Cazares H, Eberhart CG, Quinones-Hinojosa A, Scheffler B, Laterra J: c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci U S A. 2011, 108 (24): 9951-9956. 10.1073/pnas.1016912108.View ArticlePubMedPubMed CentralGoogle Scholar
- Reznik TE, Sang Y, Ma Y, Abounader R, Rosen EM, Xia S, Laterra J: Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res. 2008, 6 (1): 139-150. 10.1158/1541-7786.MCR-07-0236.View ArticlePubMedPubMed CentralGoogle Scholar
- Lal B, Xia S, Abounader R, Laterra J: Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res. 2005, 11 (12): 4479-4486. 10.1158/1078-0432.CCR-05-0166.View ArticlePubMedGoogle Scholar
- Wang SD, Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, Piccirillo S, Vescovi AL, DiMeco F, Olivi A, Eberhart CG: EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase. Oncogene. 2012, 31 (50): 5132-5143. 10.1038/onc.2012.16.View ArticlePubMedPubMed CentralGoogle Scholar
- Ying M, Sang Y, Li Y, Guerrero-Cazares H, Quinones-Hinojosa A, Vescovi AL, Eberhart CG, Xia S, Laterra J: Kruppel-like family of transcription factor 9, a differentiation-associated transcription factor, suppresses Notch1 signaling and inhibits glioblastoma-initiating stem cells. Stem Cells. 2011, 29 (1): 20-31. 10.1002/stem.561.View ArticlePubMedPubMed CentralGoogle Scholar
- Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, Pasternack GR: Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A. 1994, 91 (14): 6379-6383. 10.1073/pnas.91.14.6379.View ArticlePubMedPubMed CentralGoogle Scholar
- Orita H, Coulter J, Lemmon C, Tully E, Vadlamudi A, Medghalchi SM, Kuhajda FP, Gabrielson E: Selective inhibition of fatty acid synthase for lung cancer treatment. Clin Cancer Res. 2007, 13 (23): 7139-7145.PubMedGoogle Scholar
- Vazquez-Martin A, Colomer R, Brunet J, Menendez JA: Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting ‘HER2 super-expression’ occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Int J Oncol. 2007, 31 (4): 769-776.PubMedGoogle Scholar
- Watkins PA, Maiguel D, Jia Z, Pevsner J: Evidence for 26 distinct acyl-coenzyme A synthetase genes in the human genome. J Lipid Res. 2007, 48 (12): 2736-2750. 10.1194/jlr.M700378-JLR200.View ArticlePubMedGoogle Scholar
- Das UN: Essential fatty acids and their metabolites as modulators of stem cell biology with reference to inflammation, cancer, and metastasis. Cancer Metastasis Rev. 2011, 30 (3–4): 311-324.View ArticlePubMedGoogle Scholar
- Herrmann T, van der Hoeven F, Grone HJ, Stewart AF, Langbein L, Kaiser I, Liebisch G, Gosch I, Buchkremer F, Drobnik W, Schmitz G, Stremmel W: Mice with targeted disruption of the fatty acid transport protein 4 (Fatp 4, Slc27a4) gene show features of lethal restrictive dermopathy. J Cell Biol. 2003, 161 (6): 1105-1115. 10.1083/jcb.200207080.View ArticlePubMedPubMed CentralGoogle Scholar
- Das UN, Begin ME, Ells G: Fatty acid changes during the induction of differentiation of human promyelocytic leukemia (HL-60) cells by phorbolmyristate acetate. Prostaglandins Leukot Essent Fatty Acids. 1992, 46 (3): 235-239. 10.1016/0952-3278(92)90077-V.View ArticlePubMedGoogle Scholar
- Finstad HS, Kolset SO, Holme JA, Wiger R, Farrants AK, Blomhoff R, Drevon CA: Effect of n-3 and n-6 fatty acids on proliferation and differentiation of promyelocytic leukemic HL-60 cells. Blood. 1994, 84 (11): 3799-3809.PubMedGoogle Scholar
- Kawakita E, Hashimoto M, Shido O: Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience. 2006, 139 (3): 991-997. 10.1016/j.neuroscience.2006.01.021.View ArticlePubMedGoogle Scholar
- Varney ME, Hardman WE, Sollars VE: Omega 3 fatty acids reduce myeloid progenitor cell frequency in the bone marrow of mice and promote progenitor cell differentiation. Lipids Health Dis. 2009, 8: 9-10.1186/1476-511X-8-9.View ArticlePubMedPubMed CentralGoogle Scholar
- Hall AM, Wiczer BM, Herrmann T, Stremmel W, Bernlohr DA: Enzymatic properties of purified murine fatty acid transport protein 4 and analysis of acyl-CoA synthetase activities in tissues from FATP4 null mice. J Biol Chem. 2005, 280 (12): 11948-11954. 10.1074/jbc.M412629200.View ArticlePubMedGoogle Scholar
- Kim JH, Lewin TM, Coleman RA: Expression and characterization of recombinant rat Acyl-CoA synthetases 1, 4, and 5. Selective inhibition by triacsin C and thiazolidinediones. J Biol Chem. 2001, 276 (27): 24667-24673. 10.1074/jbc.M010793200.View ArticlePubMedGoogle Scholar
- Li H, Black PN, Chokshi A, Sandoval-Alvarez A, Vatsyayan R, Sealls W, DiRusso CC: High-throughput screening for fatty acid uptake inhibitors in humanized yeast identifies atypical antipsychotic drugs that cause dyslipidemias. J Lipid Res. 2008, 49 (1): 230-244. 10.1194/jlr.D700015-JLR200.View ArticlePubMedGoogle Scholar
- Van Horn CG, Caviglia JM, Li LO, Wang S, Granger DA, Coleman RA: Characterization of recombinant long-chain rat acyl-CoA synthetase isoforms 3 and 6: identification of a novel variant of isoform 6. Biochemistry. 2005, 44 (5): 1635-1642. 10.1021/bi047721l.View ArticlePubMedGoogle Scholar
- Stahl A, Gimeno RE, Tartaglia LA, Lodish HF: Fatty acid transport proteins: a current view of a growing family. Trends Endocrinol Metab. 2001, 12 (6): 266-273. 10.1016/S1043-2760(01)00427-1.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/401/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.